CKD Bio Corp. (063160.KS)
KRW 22500.0
(-1.96%)
KRW 22500.0
(-1.96%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.01 Billion KRW | -70.16% |
| 2022 | 16.78 Billion KRW | 26.18% |
| 2021 | 13.3 Billion KRW | -52.25% |
| 2020 | 27.86 Billion KRW | -22.97% |
| 2019 | 36.17 Billion KRW | 54.46% |
| 2018 | 23.41 Billion KRW | -5.89% |
| 2017 | 24.88 Billion KRW | -5.69% |
| 2016 | 26.38 Billion KRW | 28.62% |
| 2015 | 20.51 Billion KRW | 125.79% |
| 2014 | 9.08 Billion KRW | -38.19% |
| 2013 | 14.7 Billion KRW | -35.83% |
| 2012 | 22.9 Billion KRW | -4.06% |
| 2011 | 23.88 Billion KRW | -19.19% |
| 2010 | 29.55 Billion KRW | -0.25% |
| 2009 | 29.62 Billion KRW | 38.63% |
| 2008 | 21.37 Billion KRW | 121.1% |
| 2007 | 9.66 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 9.24 Billion KRW | 9297.38% |
| 2024 Q2 | 11.34 Billion KRW | 22.71% |
| 2024 Q3 | 43.88 Billion KRW | -20.83% |
| 2023 Q2 | 1.56 Billion KRW | -49.14% |
| 2023 Q4 | 98.36 Million KRW | -96.1% |
| 2023 FY | 5.01 Billion KRW | -70.16% |
| 2023 Q1 | 3.08 Billion KRW | 1489.39% |
| 2023 Q3 | 2.51 Billion KRW | 60.63% |
| 2022 Q3 | 6.85 Billion KRW | 103.46% |
| 2022 Q2 | 3.37 Billion KRW | -50.28% |
| 2022 Q1 | 6.78 Billion KRW | 162.5% |
| 2022 FY | 16.78 Billion KRW | 26.18% |
| 2022 Q4 | -221.93 Million KRW | -103.24% |
| 2021 Q2 | 4.7 Billion KRW | 28.59% |
| 2021 Q1 | 3.66 Billion KRW | -17.97% |
| 2021 Q3 | 2.35 Billion KRW | -50.02% |
| 2021 Q4 | 2.58 Billion KRW | 9.79% |
| 2021 FY | 13.3 Billion KRW | -52.25% |
| 2020 Q1 | 7.83 Billion KRW | -21.55% |
| 2020 Q3 | 6.49 Billion KRW | -28.5% |
| 2020 Q4 | 4.46 Billion KRW | -31.23% |
| 2020 FY | 27.86 Billion KRW | -22.97% |
| 2020 Q2 | 9.07 Billion KRW | 15.89% |
| 2019 Q1 | 7.22 Billion KRW | 14.03% |
| 2019 Q3 | 9.91 Billion KRW | 9.56% |
| 2019 Q4 | 9.98 Billion KRW | 0.71% |
| 2019 FY | 36.17 Billion KRW | 54.46% |
| 2019 Q2 | 9.04 Billion KRW | 25.23% |
| 2018 Q2 | 4.39 Billion KRW | -24.12% |
| 2018 Q3 | 6.89 Billion KRW | 56.91% |
| 2018 FY | 23.41 Billion KRW | -5.89% |
| 2018 Q1 | 5.79 Billion KRW | 2.72% |
| 2018 Q4 | 6.33 Billion KRW | -8.1% |
| 2017 Q1 | 5.86 Billion KRW | 11.57% |
| 2017 FY | 24.88 Billion KRW | -5.69% |
| 2017 Q4 | 5.63 Billion KRW | -21.61% |
| 2017 Q3 | 7.19 Billion KRW | 16.23% |
| 2017 Q2 | 6.18 Billion KRW | 5.49% |
| 2016 FY | 26.38 Billion KRW | 28.62% |
| 2016 Q4 | 5.25 Billion KRW | -12.27% |
| 2016 Q3 | 5.99 Billion KRW | -14.96% |
| 2016 Q2 | 7.04 Billion KRW | -12.85% |
| 2016 Q1 | 8.08 Billion KRW | 26.74% |
| 2015 FY | 20.51 Billion KRW | 125.79% |
| 2015 Q2 | 3.62 Billion KRW | -3.99% |
| 2015 Q3 | 6.72 Billion KRW | 85.41% |
| 2015 Q1 | 3.77 Billion KRW | 112.66% |
| 2015 Q4 | 6.38 Billion KRW | -5.15% |
| 2014 Q3 | 2.22 Billion KRW | -9.68% |
| 2014 Q2 | 2.46 Billion KRW | -6.11% |
| 2014 Q1 | 2.62 Billion KRW | -15.58% |
| 2014 Q4 | 1.77 Billion KRW | -20.1% |
| 2014 FY | 9.08 Billion KRW | -38.19% |
| 2013 FY | 14.7 Billion KRW | -35.83% |
| 2013 Q2 | 3.88 Billion KRW | 10.22% |
| 2013 Q3 | 4.18 Billion KRW | 7.77% |
| 2013 Q1 | 3.52 Billion KRW | -26.72% |
| 2013 Q4 | 3.1 Billion KRW | -25.79% |
| 2012 FY | 22.9 Billion KRW | -4.06% |
| 2012 Q4 | 4.8 Billion KRW | -30.02% |
| 2012 Q3 | 6.87 Billion KRW | 12.95% |
| 2012 Q2 | 6.08 Billion KRW | 18.29% |
| 2012 Q1 | 5.14 Billion KRW | -9.82% |
| 2011 Q1 | 8.04 Billion KRW | 10.83% |
| 2011 FY | 23.88 Billion KRW | -19.19% |
| 2011 Q4 | 5.7 Billion KRW | 10.87% |
| 2011 Q3 | 5.14 Billion KRW | 3.25% |
| 2011 Q2 | 4.98 Billion KRW | -38.08% |
| 2010 Q3 | 8.71 Billion KRW | 35.05% |
| 2010 FY | 29.55 Billion KRW | -0.25% |
| 2010 Q2 | 6.45 Billion KRW | -9.27% |
| 2010 Q1 | 7.11 Billion KRW | 7.38% |
| 2010 Q4 | 7.26 Billion KRW | -16.71% |
| 2009 Q4 | 6.62 Billion KRW | -7.12% |
| 2009 FY | 29.62 Billion KRW | 38.63% |
| 2009 Q2 | 6.71 Billion KRW | -26.65% |
| 2009 Q1 | 9.15 Billion KRW | 10.7% |
| 2009 Q3 | 7.13 Billion KRW | 6.28% |
| 2008 Q3 | 5.92 Billion KRW | 60.79% |
| 2008 Q4 | 8.26 Billion KRW | 39.46% |
| 2008 Q1 | 3.48 Billion KRW | 20.34% |
| 2008 FY | 21.37 Billion KRW | 121.1% |
| 2008 Q2 | 3.68 Billion KRW | 5.65% |
| 2007 FY | 9.66 Billion KRW | 0.0% |
| 2007 Q3 | 2.84 Billion KRW | 40.26% |
| 2007 Q1 | 1.88 Billion KRW | 0.0% |
| 2007 Q2 | 2.03 Billion KRW | 7.81% |
| 2007 Q4 | 2.89 Billion KRW | 1.74% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 89.226% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 98.624% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 97.481% |
| HANDOK Inc. | 151.36 Billion KRW | 96.69% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | 92.547% |
| Yuhan Corporation | 564.5 Billion KRW | 99.112% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 98.445% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | 78.901% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 99.401% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 93.323% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 97.482% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | 87.674% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 94.699% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 96.443% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 89.226% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | 85.568% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 93.478% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 141.594% |
| JW Holdings Corporation | 446.15 Billion KRW | 98.877% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 97.586% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 99.235% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 98.507% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 93.627% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 93.341% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 93.062% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 97.274% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 89.226% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 98.302% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 99.265% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 98.507% |
| Yuhan Corporation | 564.5 Billion KRW | 99.112% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 97.517% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 92.937% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 94.94% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 98.507% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 96.566% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 97.112% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 98.029% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 97.279% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 94.894% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 93.627% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 98.651% |
| Boryung Corporation | 333.26 Billion KRW | 98.497% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | 89.989% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 97.482% |
| JW Lifescience Corporation | 51.32 Billion KRW | 90.238% |